In fact, the serological tests in our study demonstrated a significant increase in circulating anti-SFT2D2 IgG levels in patients with schizophrenia (FC = 1.847, P < 0.0001), with a sensitivity (true positive) of 28.57% against a specificity (true negative) of 95%, suggesting that anti-SFT2D2 IgG may be indicative of a subgroup of schizophrenia. Here, SFT2D2 is linked to schizophrenia.